Skip to content
Research Article Open access CC BY 4.0

Osteopenia in HIV Positive Patients After 8 Months on Tenofovir: A Case Study

Karra Geetha, R. Sakshi, T. Chandana, Ch. Sai Chandu, T. Ramarao

Asian Journal of Advanced Research and Reports · pp. 24–29 · Published 31 May 2024

10.9734/ajarr/2024/v18i7681

Abstract

Tenofovir, a nucleotide reverse transcriptase inhibitor, is a key component of highly active antiretroviral therapy (HAART) for HIV infection. While effective in suppressing viral replication, long-term use of tenofovir has been associated with adverse effects, including bone mineral density (BMD) loss and increased risk of osteopenia and osteoporosis. Tenofovir-induced osteopenia is a significant concern in the management of HIV-infected individuals, as it can lead to increased fracture risk and reduced quality of life. We present the case of a 40-year-old female patient with HIV who was on a Tenofovir disoproxil fumarate (TDF)-containing regimen consisting ofTenofovir disoproxil fumarate, lamivudine, dolutegravir (TLD) for 8 months and developed symptoms suggestive of osteopenia. The patient presented with difficulty in walking, knee pain and swelling, hip joint pain, and limited left arm mobility, which had significantly impacted her daily activities, leading to her being bedridden for two months. Laboratory findings revealed reduced BMD in the lumbar spine and femoral neck, along with low serum vitamin D levels, supporting the diagnosis of tenofovir-induced osteopenia. The management of tenofovir-induced osteopenia involves discontinuation of TDF and initiation of alternative antiretroviral therapy, as well as supplementation with calcium and vitamin D. In this case, the patient was switched to abacavir, lamivudine, and dolutegravir, which are not associated with significant bone-related side effects. Calcium and vitamin D supplementation were also prescribed to improve bone health. This case highlights the importance of monitoring bone health in patients on TDF therapy and prompt recognition and management of osteopenia to prevent further bone loss and improve quality of life in these patients. Regular assessment of BMD and serum vitamin D levels is essential to detect osteopenia early and initiate appropriate interventions.

Tenofovir osteopenia antiretroviral therapy HIV bone mineral density

References (17)

  1. 1 Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review [DOI]
  2. 2 Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202 [DOI]
  3. 3 Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents [DOI]
  4. 4 Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral Regimen [DOI]
  5. 5 Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans [DOI]
  6. 6 Increased Rates of Bone Fracture Among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared With the US General Population, 2000-2006 [DOI]
  7. 7 Continuous antiretroviral therapy decreases bone mineral density [DOI]
  8. 8 High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study [DOI]
  9. 9 Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss [DOI]
  10. 10 The Effect of Tenofovir Disoproxil Fumarate on Bone Mineral Density: A Systematic Review and Meta-Analysis [DOI]
  11. 11 Prospective study of bone mineral density changes in aging men with or at risk for HIV infection [DOI]
  12. 12 Association of Higher Plasma Vitamin D Binding Protein and Lower Free Calcitriol Levels with Tenofovir Disoproxil Fumarate Use and Plasma and Intracellular Tenofovir Pharmacokinetics: Cause of a Functional Vitamin D Deficiency? [DOI]
  13. 13 Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals [DOI]
  14. 14 Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events [DOI]
  15. 15 Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy [DOI]
  16. 16 Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study [DOI]
  17. 17 High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

80

Page views

0

PDF downloads

21

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.